Generic winners don’t “wait”—they execute. Here’s the Paragraph IV playbook.
If you’re in pharma, you already know the headline: Paragraph IV is where generic manufacturers can win 180 days of exclusivity—and potentially reshape a product’s commercial …

The Patent Dance is no longer a dance—it’s a chess match.
If you’re a biologics or biosimilar applicant, the BP(C)IA litigation landscape has shifted from “file fast and respond” to “anticipate, sequence, and win on procedure.” The playbook isn’t jus…

Big Pharma isn’t talking about it—but drug patent data is quietly becoming the most important forecasting tool in healthcare.
Here’s the uncomfortable truth: most “supply chain forecasts” still start with demand assumptions, then work backward. But in …

Patent cliffs aren’t just a legal event—they’re a supply-chain event.
When a drug’s exclusivity ends, the industry often treats it like a spreadsheet moment: update forecasts, watch competitors launch, adjust pricing assumptions. But the real disrupt…

Generic drug margins are getting squeezed from every direction—and the industry is starting to fight back in ways that look less like “wait and see” and more like a full-scale strategy reset.
Here’s the hook: the generic business model used to be simpl…

Branded pharma’s revenue model is under siege—and the threats aren’t subtle.
If you’re still thinking about “patent cliffs” as a single event, you’re missing the bigger picture. The branded revenue machine is facing a stack of brutal, compounding press…

Generic drug competition isn’t won in the lab—it’s won in the fine print.
If you’ve ever wondered how generic manufacturers consistently time their launches with surgical precision, the answer is hiding in plain sight: the FDA’s Orange Book.
In a rec…

Biopharma hiring is broken in a subtle way.
Most teams still treat IP as a “legal function” and talent as a “headcount problem.” But in modern drug development, patents aren’t just filings—they’re operating systems. They determine who owns what, who ca…

The generic cliff doesn’t just “happen.” Pharma engineers it.
For years, the public narrative has been simple: patents expire, generics arrive, revenues fall. But the reality—especially for branded drug makers—is more like a chess match played years …

Patent thickets are the new moat—and biologics are the new battleground.
If you’ve ever wondered why some blockbuster biologic therapies seem to face a “wall” of delays long after the original patent term should have ended, the answer is often not on…